893566-74-0

Basic information

• Product Name: 6-BROMO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 6-BROMO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER;tert-butyl 6-broMo-1,2,3,4-tetrahydroisoquinoline-2-carboxylate;2-Boc-6-bromo-3,4-dihydro-1H-isoquinoline;tert-Butyl 6-bromo-3,4-dihydroisoquinoline-2(1H);6-bromo-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline;2-Boc-6-bromo-1,2,3,4-tetrahydroisoquinoline
• CAS NO: 893566-74-0
• Molecular Formula: C₁₄H₁₈BrNO₂
• Molecular Weight: 312.21
• Product Categories: CHIRAL CHEMICALS
• Mol File: 893566-74-0.mol
• Article Data: 32

Chemical Properties

• Boiling Point: 374.2 °C at 760 mmHg
• Flash Point: 180.1 °C
• Appearance: /
• Density: 1.353g/cm³
• Vapor Pressure: 8.48E-06mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: 2-8°C
• PKA: -1.56±0.20(Predicted)
• CAS DataBase Reference: 6-BROMO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER(893566-74-0)
• EPA Substance Registry System: 6-BROMO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER(893566-74-0)

Safety Data

• Hazardous Substances Data: 893566-74-0(Hazardous Substances Data)

Usage

General Description

6-Bromo-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester is a chemical compound that belongs to the class of isoquinoline carboxylic acid esters. It is commonly used in the synthesis of pharmaceuticals and organic compounds, and has potential applications in medicinal and agricultural chemistry. The tert-butyl ester group in the molecule provides protection and stability to the carboxylic acid functionality, making it a valuable building block for the synthesis of complex molecules. 6-BROMO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER has also been studied for its potential biological activities and may have use in drug discovery and development. Overall, 6-Bromo-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester is an important and versatile chemical compound with various applications in organic and medicinal chemistry.

InChI:InChI=1/C14H18BrNO2/c1-14(2,3)18-13(17)16-7-6-10-8-12(15)5-4-11(10)9-16/h4-5,8H,6-7,9H2,1-3H3

Upstream product

• 34784-05-9 6-bromo-isoquinoline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 58971-11-2 2-(3-bromophenyl)ethanamine 
• 31938-07-5 (3-bromophenyl)acetonitrile 
• 226942-29-6 6-bromo-1,2,3,4-tetrahydroisoquinoline 
• 215798-19-9 6-bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 164148-92-9 tert-butyl 6-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 75416-51-2 8-bromo-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 170097-67-3 2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 
• 166398-33-0 tert-butyl 6-cyano-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 166398-34-1 1,2,3,4-tetrahydroisoquinoline-6-carbonitrile 
• 893566-72-8 6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 1008517-86-9 6-[2-(toluene-4-sulfonyloxy)-ethyl]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 

Relevant articles and documents

Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma

Histone deacetylase 6 (HDAC6) has been targeted in clinical studies for anticancer effects due to its role in oncogenic transformation and metastasis. Through a second-generation structure–activity relationship (SAR) study, the design, and biological eval

SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS

Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.